Cornerstone Therapeutics Inc. (NASDAQ:CRTX)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.

Recs

1
Player Avatar spikenailz (91.43) Submitted: 7/26/2007 10:42:05 AM : Outperform Start Price: $2.30 CRTX Score: +126.44

They have had huge success with their asthma meds and they have some new ones in late stages of trials. This company has no where to go but up.

Featured Broker Partners


Advertisement